p53 Is not inactivated in B6C3F1 mouse vascular tumors arising spontaneously or associated with long-term administration of the thiazolidinedione troglitazone

Toxicology and Applied Pharmacology

Volumn 156, Issue 2, 1999, Pages 106-112

  Duddy, Steven K ^a   Parker, Robert F ^a   Bleavins, Michael R ^a   Gough, Alexander W ^a   Rowse, Paul E ^a   Gorospe, Susanne ^a   Dethloff, Lloyd A ^a   De La Iglesia, Felix A ^a  

^a PFIZER INC   (United States)

Author keywords

B6C3F1 mouse; Hemangiosarcoma; P53; Thiazolidinedione; Troglitazone

Indexed keywords

DNA; PROTEIN P53; TROGLITAZONE;

ANGIOSARCOMA; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE INACTIVATION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MALE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

EID: 0032970818     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1999.8631     Document Type: Article

References (50)

1. Barbin A., Froment O., Boivin S., Marion M. J., Belpoggi F., Maltoni C., Montesano R. p53 gene mutation pattern in rat liver tumors induced by vinyl chloride. Cancer Res. 57:1997;1695-1698.
2. Bogdanffy M. S., Makovec G. T., Frame S. R. Inhalation oncogenicity bioassay in rats and mice with vinyl fluoride. Fundam. Appl. Toxicol. 26:1995;223-238.
3. Booth C. J., Sundberg J. P. Hemangiomas and hemangiosarcomas in inbred laboratory mice. Lab. Anim. Sci. 45:1995;497-502.
4. Brandt-Rauf P. W., Chen J. M., Marion M. J., Smith S. J., Luo J. C., Carney W., Pincus M. R. Conformational effects in the p53 protein of mutations induced during chemical carcinogenesis: Molecular dynamic and immunologic analysis. J. Protein Chem. 15:1996;367-376.
5. Caamano J., Zhang S. Y., Rosvold E. A., Bauer B., Klein-Szanto A. J. P. p53 Alterations in human squamous cell carcinomas and carcinoma cell lines. Am. J. Pathol. 142:1993;1131-1139.
6. Chandra M., Frith C. H. Spontaneous neoplasms in B6C3F1 mice. Toxicol. Lett. 60:1995;91-98.
7. Crispens C. G. Handbook on the Laboratory Mouse. 1975;Charles C. Thomas Press, Springfield.
8. Donehower L. S., Harvey M., Slagle B. L., McArthur M. J., Montgomery C. A. Jr., Burel J. S., Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 356:1992;215-221.
9. Duddy S. K., Gorospe S., Bleavins M. R. Genetic analysis of multiple loci in microsamples of fixed paraffin-embedded tissue. Toxicol. Sci. 46:1999;317-323.
10. Enzinger F., Weiss S. Soft Tissue Tumors. 1995;Mosby Press, St. Louis.
11. Falk H. Vinyl chloride-induced hepatic angiosarcoma. Princess Takamatsu Symp. 18:1987;39-46.
12. Falk H., Telles N. C., Ishak K. G., Thomas L. B., Popper H. Epidemiology of thorotrast-induced hepatic angiosarcoma in the United States. Environ. Res. 18:1979;65-73.
13. Gart J. J., Chu K. C., Tarone R. E. Statistical issues in interpretation of chronic bioassay tests for carcinogenicity. J. Natl. Cancer Inst. 62:1979;957-974.
14. Ghazzi M. N., Perez J. E., Antonucci T. K., Driscoll J. H., Huang S. M., Faja B. W., Whitcomb R. W. Cardiac and glycemic benefits of troglitazone treatment in NIDDM: The Troglitazone Study Group. Diabetes. 46:1997;433-439.
15. Gottlieb T. M., Oren M. p53 in growth control and neoplasia. Biochim. Biophys. Acta. 1287:1996;77-102.
16. Greaves P. Histopathology of Preclinical Toxicity Studies: Interpretation and Relevance in Drug Safety Evaluation. 1990;Elsevier, New York.
17. Harris C. C. p53 tumor suppressor gene: At the crossroads of molecular carcinogenesis, molecular epidemiology, and cancer risk assessment. Environ. Health Perspect. 104:1996;435-439.
18. Hisaoka M., Kouho H., Aoki T., Hashimoto H. DNA flow cytometric and immunohistochemical analysis of proliferative activity in spindle cell haemangioendothelioma. Histopathology. 27:1995;451-456.
19. Hollstein M., Marion M. J., Lehman T., Welsh J., Harris C. C., Martel-Planche G., Kusters I., Montesano R. p53 mutations at A:T base pairs in angiosarcomas of vinyl chloride-exposed factory workers. Carcinogenesis. 15:1994a;1-3.
20. Hollstein M., Rice K., Greenblatt M. S., Soussi T., Fuchs R., Sørlie T., Hovig E., Smith-Sørensen B., Montesano R., Harris C. C. Database of p53 somatic mutations in human tumors and cell lines. Nucleic Acids Res. 22:1994b;3551-3555.
21. Hu E., Kim J. B., Sarraf P., Spiegelman B. M. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARγ Science (Washington, D.C.). 274:1996;2100-2103.
22. Inohara S. Immunohistochemical localization of p53 protein in malignant hemangioendothelioma. Acta Dermato-Venereol. 74:1994;161-162.
23. Ito Y., Kojiro M., Nakashima T., Mori T. Pathomorphologic characteristics of 102 cases of thorotrast-related hepatocellular carcinoma, cholangiocarcinoma, and hepatic angiosarcoma. Cancer. 15:1988;1153-1162.
24. Iwata J., Sonobe H., Furihata M., Ido E., Ohtsuki Y. High frequency of apoptosis in infantile capillary haemangioma. J. Pathol. 179:1996;403-408.
25. Jacks T., Remington L., Williams B. O., Schmitt E. M., Halachmi S., Bronson R. T., Weinberg R. A. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4:1994;1-7.
26. Kemp C. J. Hepatocarcinogenesis in p53-deficient mice. Mol. Carcinog. 12:1995;132-136.
27. Kreutzer D. A., Essigmann J. M. in vivo. Proc. Natl. Acad. Sci. USA. 95:1998;3578-3582.
28. Lambe K. G., Tugwood J. D. A human peroxisome-proliferator-activated receptor-gamma is activated by inducers of adipogenesis, including thiazolidinedione drugs. Eur. J. Biochem. 239:1996;1-7.
29. Law R. E., Meehan W. P., Xi X. P., Graf K., Wuthrich D. A., Coats W., Faxon D., Hsueh W. A. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J. Clin. Invest. 98:1996;1897-1905.
30. Meis-Kindblom J. M., Kindblom L. G. Angiosarcoma of soft tissue: A study of 80 cases. Am. J. Surg. Pathol. 22:1998;683-697.
31. Midgley C. A., Fisher C. J., Bartek J., Vojtesek B., Lane D. P., Barnes D. M. Analysis of p53 expression in human tumours: An antibody raised against human p53 expressed inE. coli. J. Cell Sci. 101:1992;183-189.
32. Mitsunaga S. I., Zhang S. Y., Ruggeri B. A., Giminez-Conti I., Robles A. I., Conti C. J., Klein-Szanto A. J. P. Positive immunohistochemical staining of p53 and cyclin D in advanced mouse skin tumors, but not in precancerous lesions produced by benzo[a. Carcinogenesis. 16:1995;1629-1635.
33. Naka N., Tomita Y., Nakanishi H., Araki N., Hongyo T., Ochi T., Aozasa K. Mutations of p53 tumor-suppressor gene in angiosarcoma. Int. J. Cancer. 71:1997;952-955.
34. National Toxicology Program, 1997, Testing Information and Study Results Database, http://ntp-server.niehs.nih.gov/.
35. Noguchi N., Sakai H., Kato Y., Tsuchiya J., Yamamoto Y., Niki E., Horikoshi H., Kodama T. Inhibition of oxidation of low density lipoprotein by troglitazone. Atherosclerosis. 123:1996;227-234.
36. Peto R., Pike M. C., Day N. E. Guidelines for simple, sensitive significance tests for carcinogenic effects in long-term animal experiments. IARC Monogr. Eval. Carcinog. Risk Chem. Hum. 2:1980;311-426.
37. Popper H., Thomas L. B., Telles N. C., Falk H., Selikoff I. J. Development of hepatic angiosarcoma in man induced by vinyl chloride, thorotrast, and arsenic: Comparison with cases of unknown etiology. Am. J. Pathol. 92:1978;349-376.
38. Retèl J., Hoebee B., Braun J. E. F., Lutgerink J. T., van den Akker E., Wanamarta A. H., Joenje H., Lafleur M. V. M. Mutational specificity of oxidative DNA damage. Mutat. Res. 299:1993;165-182.
39. Soini Y., Welsh J. A., Ishak K. G., Bennett W. P. p53 Mutations in primary hepatic angiosarcomas not associated with vinyl chloride exposure. Carcinogenesis. 16:1995;2879-2881.
40. Soong R., Robbins P. D., Dix B. R., Grieu F., Lim B., Knowles S., Williams K. E., Turbett G. R., House A. K., Iacopetta B. J. Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Hum. Pathol. 27:1996;1050-1055.
41. Takahashi K., Mulliken J. B., Kozakewich P. W., Rodgers R. A., Folkman J., Ezekowitz R. A. B. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J. Clin. Invest. 93:1994;2357-2364.
42. Terada T., Shimizu K., Izumi R., Nakanuma Y. p53 Expression in formalin-fixed, paraffin-embedded archival specimens of intrahepatic cholangiocarcinoma: Retrieval of p53 antigenicity by microwave oven heating of tissue sections. Mod. Pathol. 7:1994;249-252.
43. Til H. P., Feron V. J., Immel H. R. Lifetime (149-week) oral carcinogenicity study of vinyl chloride in rats. Food Chem. Toxicol. 29:1991;713-718.
44. Tontonoz P., Singer S., Forman B. M., Sarraf P., Fletcher J. A., Fletcher C. D. M., Brun R. P., Mueller E., Altiok S., Oppenheim H., Evans R. M., Spiegelman B. M. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor. Proc. Natl. Acad. Sci. USA. 94:1997;237-241.
45. Trivers G. E., Cawley H. L., DeBenedetti V. M., Hollstein M., Marion M. J., Bennett W. P., Hoover M. L., Prives C. C., Tamburro C. C., Haris C. C. Anti-p53 antibodies in sera of workers occupationally exposed to vinyl chloride. J. Natl. Cancer Inst. 87:1995;1400-1407.
46. van Gijssel H. E., Maassen C. B. M., Mulder G. J., Meerman J. H. N. p53 protein expression by hepatocarcinogens in the rat liver and its potential role in mitoinhibition of normal hepatocytes as a mechanism of tumor promotion. Carcinogenesis. 18:1997;1027-1033.
47. Wagner E. F., Risau W. Oncogenes in the study of endothelial cell growth and differentiation. Semin. Cancer Biol. 5:1994;137-145.
48. Whysner J., Conaway C. C., Berna L., Williams G. M. Vinyl chloride mechanistic data and risk assessment: DNA reactivity and cross-species quantitative risk extrapolation. Pharmacol. Ther. 1:1996;7-28.
49. Zhang L., Cui X., Schmitt K., Hubert R., Navidi W., Arnheim N. Whole genome amplification from a single cell: Implications for genetic analysis. Proc. Natl. Acad. Sci. USA. 89:1992;5847-5851.
50. Zietz C., Rössle M., Haas C., Sendelhofert A., Hirschmann A., Stürzl M., Löhrs U. MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am. J. Pathol. 153:1998;1425-1433.